EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Reversible downregulation of HLA class I in adenoid cystic carcinoma

Annie Li, Bianca L Gonda, Elizabeth M Codd, Adam von Paternos, Dawn R Mitchell, Markus D Herrmann, Prinjali Kalyan, Samantha E Flynn, Thuc Q Dzu, Chengzhuo Gao, Edwin Zhang, Julia J Mendel und 17 weitere

Journal for ImmunoTherapy of Cancer · 2025-04 · 13 (4) · e011380

DOI: 10.1136/jitc-2024-011380 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 20.04.2025. Verfasst von Annie Li und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Carcinoma, Adenoid Cystic, Histocompatibility Antigens Class I. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Adenoid Cystic Carcinoma Research Foundation, Takeda Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adenoid cystic carcinoma (ACC) is a rare, but lethal cancer with low response rates to systemic therapies, such as cytotoxic chemotherapy and immune-checkpoint inhibitors (ICIs). Despite extensive clinical trials, no effective treatments for patients with recurrent or metastatic ACC are available, and ACC mortality rates remain poor.

Methods

We employed automated multiplex immunofluorescence (mIF), single-cell RNA sequencing (scRNA-seq) Gene Expression analysis, RNA in-situ hybridization, and spatial transcriptomics analysis to characterize the immune landscape of ACC tumors, ACC metastasis, and normal tissues from regions where ACCs arise. Based on results from these studies, we treated freshly resected ACCs with interferon-γ or a stimulator of the interferon genes (STING) agonist in vitro. Additionally, we included one patient with ACC in a phase 1 clinical study of a novel STING agonist (dazostinag) plus pembrolizumab.

Results

The mIF analysis revealed that ACC tumors are immunologically “cold”, with few tumor-infiltrating T-lymphocytes and low programmed death-ligand 1 (PD-L1) expression. The most striking finding was a very low beta-2-microglobulin (B2M) expression in nearly all ACCs, with only focal expression found in some ACC metastases. mIF and RNA sequencing analyses of normal salivary gland and breast tissues revealed a p63+, NFIB+, basal duct cell population, with similarly low B2M/human leukocyte antigen (HLA) class I expression. Spatial transcriptomics analysis of the focally B2M-positive ACC metastases uncovered the genetic pathway driving upregulation of B2M, an interferon-γ program mediating the reintroduction of HLA-I/B2M; the significantly upregulated genes included IRF1, GBP1, and TAP1 . On short-term treatment of primary ACC tissues in vitro with interferon-γ or a STING agonist, we observed strongly upregulated HLA class I/B2M expression. Moreover, treatment of a patient with recurrent, metastatic breast ACC with a STING agonist and pembrolizumab led to a partial response with a 70% tumor reduction.

Conclusions

Low B2M/HLA class I expression may explain why ACCs are immunologically cold and the lack of response to ICIs. Our findings suggest that the normal cell of ACC origin exists in a B2M/HLA-class I low state, and that pharmacologic manipulation with immune activators, such as STING agonists, can restore HLA/B2M in ACCs, as supported by the promising response observed in a patient with metastatic ACC. These findings indicate a potential path to urgently needed immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Adenoid CysticHistocompatibility Antigens Class IHumansDown-RegulationFemaleMaleMiddle Aged

Stichwörter der Autor:innen

Head and Neck CancerHuman leukocyte antigen - HLAImmune modulatoryMajor histocompatibility complex - MHC

Substanzen

Histocompatibility Antigens Class I

Autor:innen und Institutionen

  • Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Otolaryngology, Head and Neck Surgery, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Masachusetts, USA.
  • Department of Medicine, Hematology-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Oncology Development, Takeda Pharmaceuticals, Development Center Americas Inc, Lexington, Massachusetts, USA.
  • Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA aiafrate@mgb.org.

Förderung

  • Adenoid Cystic Carcinoma Research Foundation
  • Takeda Oncology

Zitieren

APA

Li, A., Gonda, B. L., Codd, E. M., von Paternos, A., Mitchell, D. R., Herrmann, M. D., Kalyan, P., Flynn, S. E., Dzu, T. Q., Gao, C., Zhang, E., Mendel, J. J., Thierauf, J. C., Sadow, P. M., Denize, T., Yang, D., Fintelmann, F. J., Fordham, J. A., Merkin, R. D., …, & Iafrate, A. J. (2025). Reversible downregulation of HLA class I in adenoid cystic carcinoma. Journal for ImmunoTherapy of Cancer, 13(4), e011380. https://doi.org/10.1136/jitc-2024-011380

Vancouver

Li A, Gonda BL, Codd EM, von Paternos A, Mitchell DR, Herrmann MD, et al. Reversible downregulation of HLA class I in adenoid cystic carcinoma. Journal for ImmunoTherapy of Cancer. 2025;13(4):e011380. doi:10.1136/jitc-2024-011380

BibTeX
@article{Li2025,
  author = {Li, Annie and Gonda, Bianca L and Codd, Elizabeth M and von Paternos, Adam and Mitchell, Dawn R and Herrmann, Markus D and Kalyan, Prinjali and Flynn, Samantha E and Dzu, Thuc Q and Gao, Chengzhuo and Zhang, Edwin and Mendel, Julia J and Thierauf, Julia C and Sadow, Peter M and Denize, Thomas and Yang, Diane and Fintelmann, Florian J and Fordham, Jo Anne and Merkin, Ross D and Bhan, Atul K and Huang, Yu-Chung and Raizer, Jeffrey and Faquin, William C and Faden, Daniel L and Gao, Xin and Park, Jong Chul and Wirth, Lori J and Kaluziak, Stefan T and Iafrate, A John},
  title = {Reversible downregulation of HLA class I in adenoid cystic carcinoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {4},
  pages = {e011380},
  doi = {10.1136/jitc-2024-011380}
}
Kostenlos starten →